Dr Sanjiv Agarwala analyzes data from 2 studies showing that the first-line combination of nivolumab plus ipilimumab demonstrates deep and sustained confirmed responses, as well as improved overall survival compared with monotherapy, in patients with metastatic uveal melanoma.
Related Items
Conference Correspondent published on December 16, 2021 in Dual IO 2021 Year in Review
Conference Correspondent published on December 15, 2021 in Dual IO 2021 Year in Review